Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Decaffeinated green tea extract is a concentrated herbal supplement derived from the leaves of Camellia sinensis with most or all caffeine removed. It is standardized to contain high levels of catechins, particularly epigallocatechin gallate (EGCG), which provides potent antioxidant support for cellular health. EGCG and other polyphenols in the extract are believed to exert their effects by neutralizing free radicals and modulating gene expression and oxidative stress pathways. Decaffeinated green tea extract has been studied for its potential benefits in supporting cardiovascular health, metabolic function (including glucose and lipid metabolism), kidney function in diabetic nephropathy, and possible chemopreventive properties against certain cancers[2][4][5][8]. The mechanism of action primarily involves antioxidant activity through scavenging reactive oxygen species and influencing cellular signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on decaffeinated green tea extract.